These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8511441)

  • 21. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-sided hypothesis testing: simultaneous testing of superiority, equivalence and inferiority.
    Goeman JJ; Solari A; Stijnen T
    Stat Med; 2010 Sep; 29(20):2117-25. PubMed ID: 20658478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weighted false discovery rate controlling procedures for clinical trials.
    Benjamini Y; Cohen R
    Biostatistics; 2017 Jan; 18(1):91-104. PubMed ID: 27445132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factorial designs: a graphical aid for choosing study designs accounting for interaction.
    Byth K; Gebski V
    Clin Trials; 2004; 1(3):315-25. PubMed ID: 16279257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sample size determination using an interim analysis.
    Bristol DR
    J Biopharm Stat; 1993 Sep; 3(2):159-66. PubMed ID: 8220401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(2):201-13. PubMed ID: 17365218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Planning survival studies to compare a treatment to an active control.
    Bristol DR
    J Biopharm Stat; 1993 Sep; 3(2):153-8. PubMed ID: 8220400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tests of non-null hypothesis on proportions for stratified data.
    Zhao G
    Stat Med; 2008 Apr; 27(9):1429-46. PubMed ID: 17668916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A note on the power of Fisher's least significant difference procedure.
    Meier U
    Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials.
    Cheng Y; Shen Y
    Biometrics; 2004 Dec; 60(4):910-8. PubMed ID: 15606411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy evaluation for monotherapies in two-by-two factorial trials.
    Hung HM; Chi GY; O'Neill RT
    Biometrics; 1995 Dec; 51(4):1483-93. PubMed ID: 8589235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An efficient and exact approach for detecting trends with binary endpoints.
    Shan G; Ma C; Hutson AD; Wilding GE
    Stat Med; 2012 Jan; 31(2):155-64. PubMed ID: 22162106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cumulative statistical power for hierarchical comparisons to evaluate two combination drug doses.
    Matsukura T; Koch GG
    J Biopharm Stat; 2008; 18(4):750-72. PubMed ID: 18607806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of response surface methodology and factorial designs to clinical trials for drug combination development.
    Stewart WH
    J Biopharm Stat; 1996 Jul; 6(3):219-30. PubMed ID: 8854227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On sample size estimation and re-estimation adjusting for variability in confirmatory trials.
    Wu PS; Lin M; Chow SC
    J Biopharm Stat; 2016; 26(1):44-54. PubMed ID: 26378970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inference following designs which adjust for imbalances in prognostic factors.
    Barbáchano Y; Coad DS
    Clin Trials; 2013 Aug; 10(4):540-51. PubMed ID: 23832671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A method of designing clinical trials for combination drugs.
    Pigeon JG; Copenhaver MD; Whipple JP
    Stat Med; 1992 Jun; 11(8):1065-74. PubMed ID: 1496194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incomplete factorial designs for randomized clinical trials.
    Byar DP; Herzberg AM; Tan WY
    Stat Med; 1993 Sep; 12(17):1629-41. PubMed ID: 8235181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia.
    Paul M; Soares-Weiser K; Grozinsky S; Leibovici L
    Cochrane Database Syst Rev; 2002; (2):CD003038. PubMed ID: 12076467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.